Hologic has finalized its acquisition of Endomagnetics, a privately owned company headquartered in the UK that specializes in technologies for breast cancer surgery. The deal, valued at around $310 million, marks a strategic expansion for Hologic into the field of breast surgery.
The acquisition specifically bolsters Hologic’s existing portfolio with Endomagnetics’ innovations, which include wireless tools for breast surgery localization and lymphatic tracing. Notable additions to Hologic’s lineup now include the Magseed marker, the Magtrace lymphatic tracer, and the Sentimag platform. According to Hologic, these new products significantly enhance the options available to breast surgeons and radiologists, aiming to advance the effectiveness and precision of breast cancer treatments.
Related topics:
